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Viral Hepatitis in Patients Infected With Human Immunodeficiency Virus
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From 1992 to 1995 we studied 232 (69% male, 87% Caucasian) anti-human
immunodeficiency virus (anti-HIV) positive Brazilian patients, through a questionnaire;
HIV had been acquired sexually by 50%, from blood by 32%, sexually and/or from blood by
16.4% and by an unknown route by 1.7%. Intravenous drug use was reported by 29%; it
was the most important risk factor for HIV transmission. The alanine aminotransferase
quotient (qALT) was >1 for 40% of the patients, 93.6% had anti-hepatitis A virus antibody,
5.3% presented hepatitis B surface antigen, 44% were anti-hepatitis B core antigen positive
and 53.8% were anti-hepatitis C virus (anti-HCV) positive. The anti-HCV test showed a
significant association with qALT>1. Patients for whom the probable HIV transmission
route was blood had a 10.8 times greater risk of being anti-HCV positive than patients
infected by other routes. Among 30 patients submitted to liver biopsy, 18 presented chronic
hepatitis.
Key Words: Hepatitis C virus, human immunodeficiency virus, alanine aminotransferase
quotient, anti-hepatitis A antibody, hepatitis B surface antigen, anti-hepatitis B core antigen
(anti-HBc).
Acquired immunodeficiency syndrome (AIDS) is
characterized by a profound defect in cell-mediated
immunity [1], which results in opportunistic infections
and neoplasms that frequently involve the liver [2].
Risk factors and forms of transmission for human
immunodeficiency virus (HIV) and hepatotropic
viruses are often the same, which explains the high
frequency of co-infection involving these two agents.
Hepatitis A virus (HAV) infection is common in both
homosexual men [3] and intravenous drug users (IVDU)
[4]. Like HIV, hepatitis B virus (HBV), hepatitis C virus
(HCV) and hepatitis delta virus (HDV) can be spread
both by needles and sexually [5].
The prevalence of HCV infection among HIV-
seropositive subjects ranges from 4% to 67% [5],
and although the sexual transmission of HCV is
uncommon it can occur in patients co-infected with
HIV [6-7], although, unlike HBV and HIV, HCV is
not easily transmitted by homosexual intercourse [8].
Some studies have indicated that HIV infection
accelerates the natural course of HCV infection and
causes rapid progression to cirrhosis [9].
We investigated the etiologic agent, risk factors,
clinical features, biochemical and immunological test
results, liver biopsies and histopathological lesions
of viral hepatitis in HIV-infected patients in order
better understand the interaction between these two
viral agents in Brazilian patients.
Materials and Methods
The study group consisted of 232 Brazilian patients
from the city of Campinas (São Paulo state, Brazil)
who had been assessed as positive at least twice in
anti-HIV EIA-2 tests between 1992 and 1995. More
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than 2/3 (69.4%) were men and 30.6% were women,
with ages ranging from 17 to 63 years (mean = 30.8
years); 87% were Caucasian and 13% were Afro-
Brazilian. According to the Center for Disease Control
(CDC) criteria, 49.5% of the patients belonged to
Group II, 30.2% to Group III and 20.3% to Group
IV.
All patients were interviewed using a standard
questionnaire designed to identify a series of
parameters, including known risk factors for HIV
infection, such as previous blood transfusion,
intravenous drug use (IVDU), sexual habits, sexual
intercourse with HIV-infected or HIV-suspected
partners, tattoos, previous acupuncture, previous
surgeries and use of intravenous medication.
Symptoms related to viral hepatitis were also
evaluated, e.g. fever, nausea, vomiting, previous
jaundice, fat intolerance, diarrhea, hematemesis,
alcohol abuse and contact with hepatotoxins. All
group members also underwent a complete physical
examination.
At the first clinical evaluation a hemogram was
made, and the levels of alanine aminotransferase
(ALT), aspartate aminotransferase (AST), alkaline
phosphatase (AP), bil irubin, albumin and
gammaglobulin were assessed. Prothrombin activity
was also evaluated. ALT activity was determined in
each serum sample by the COBAS-MIRA
automated assay (ROCHE) and the results
expressed as the ALT quotient (qALT), calculated
by dividing the ALT level in the sample by the
maximum normal value for the method. When the
ALT value was elevated, qALT was always>1.
The serum samples were also assessed for
immunoglobulin-G (IgG) and immunoglobulin-M
(IgM) anti-HAV using the “HAVAB-EIA”/“HAVAB-
M” kit; HBsAg was quantified using the Auszyme
Monoclonal kit, anti-HBcAg with the Corzyme kit,
anti-HBsAg with the Ausab kit (Abbott) and anti-
HCV with a second generation HCV EIA (All kits
were from Abbott Laboratories, North Chicago, IL.,
USA).
Liver biopsy was performed on all patients
(n=30) with qALT>1.5 times the normal value, or
who presented hepatomegaly in the physical
examination, or who were anti-HCV positive with
elevated ALT, or HBsAg positive with elevated ALT
or to investigate patients with fever of unknown
origin. Diagnoses were: normal liver (NL), chronic
persistent hepatitis (CPH), chronic active hepatitis
(CAH), chronic lobular hepatitis (CLH), minimal
changes (MC), liver cirrhosis (LC) or other non-
related lesions. CAH was classified as mild,
moderate or intense. Hematoxylin-eosin, Grocott-
Gomori, Masson’s trichrome, Ziehl-Neelsen and
Perls’s Prussian staining was also used.
Statistical analysis. Chi-squared analyses (or
Fisher’s exact test when indicated) were used to
compare the risk factors for HIV infection and
serological tests for HCV and HBV. The EPI INFO
program was used to calculate the results, with p ≤
0.05 being considered statistically significant. The
relative odds ratio was calculated to compare the
strength of the association of a positive anti-HCV
result with the different risk factors. A logistic
regression model (SAS program) was used to assess
risk factors for qALT > 1. All percentages were
calculated using n=232 patients, unless otherwise
indicated.
Results
The questionnaire completed by the 232 patients
showed that the most likely HIV acquisition routes
were as follows: sexual intercourse for 50% of the
patients, from infected blood for 32%, sexually and/
or from infected blood for 16.3% and by unknown
routes for 1.7%. In 29% of the patients IVDU was
the most important risk factor found. Other risk
factors were: heterosexual intercourse with an HIV-
infected partner for 17%, homosexual intercourse
for 13.4%, promiscuous heterosexual practices for
11%, promiscuous heterosexual practices and IVDU
for 7%, male bisexuality for 5% and sexual
intercourse with a person at risk of HIV infection
for 3.4%. Together these factors accounted for 86%
of all cases.
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Table 1. Biochemical results for HIV infected patients (n)
Table 3. Positive serological tests for hepatitis virus B (HBV) and C (HCV) according to HIV transmission
route
Viral Hepatitis and HIV
Table 2. Serological tests for hepatitis virus A, B and C (HAV, HBV, HCV, respectively) in HIV-infected
patients (n)
Biochemical tests Abnormal1 Normal Total
n % n % n %
Alanine aminotransferase (ALT) 92 40.0 140 60.0 232 100
Aspartate aminotransferase (AST) 49 21.0 182 79.0 231 100
Alkaline phosphatase (AP) 17  8.0 195 92.0 212 100
Total bilirubin  9  5.6 153  94.4 162 100
Albumin 10  5.0  92 95.0 202 100
Gamma-globulin 131 66.0  67 34.0 198 100
(1)All values were above the upper normal value for the method, except for albumin which was below the lower
normal value for the method.
Serologic tests Positive Negative Indeterminate Total
n % n % n % n %
IgM anti-HAV 01 0.6 155 99.4 — — 156 100
IgG anti-HAV 146 93.6 10 6.4 — — 156 100
HbsAg 12 5.3 211 93.4 3 1.3 226 100
Anti-HbcAg 100 44.0 126 56.0 — — 226 100
Anti-HbsAg 79 35.3 145 64.7 — — 224 100
Anti-HCV 119 53.8 100 45.2 2 1.0 221 100
Positive serologic test Blood transmission Sexual transmission
n % n %
Anti-HbcAg 5 15.6 26 66.7
Anti-HCV 27 84.4 13 33.3
Total (n) 32 100.0 39 100.0
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Table 4. Probable risk factors involved in hepatic lesions based on the alanine aminotransferase quotient
(qALT) of patients (n)
Table 5. Liver biopsy results for HIV positive patients (n).
Viral Hepatitis and HIV
Risk Factor for hepatic lesion q ALT>1 q ALT ≤ 1 Total
n % n % n %
No risk factors 5 5.4 49  35.0 54 23.3
One risk factor 42 45.6 50  35.7 92 39.6
HBV(HbsAg+) 2 2.2 — —  2  0.9
HCV(anti-HCV +) 27 29.3 27  19.3 54 23.3
Hepatotoxic drugs 12 13.0 17  12.1 29 12.5
Use of illicit drugs1 1 1.1  1  0.7  2  0.9
Alcohol abuse — —  5  3.6  5  2.1
Two risk factors 29 31.5 22  15.7 51  22.0
HBV + HCV — —  1 0.7  1  0.4
HBV + other — —  1 0.7  1  0.4
HCV + other 29 31.5  20  14.3 49 21.1
Two or more non-viral risk factors 2 2.2  5  3.6  7  3.0
HBV + HCV + other2 4 4.4  3  2.1  7  3.0
All factors 1 1.1 — —  1  0.4
Serological tests not made 9 9.8  11  7.8 20  8.6
Total 92 100.0 140 100.0 232 100.0
(1)Illicit drug = cannabis or cocaine (as snuff or intravenously).
(2)Other = hepatotoxic drug, illicit drug or alcohol abuse.
Histopathological Features n %
Chronic active hepatitis (CAH) 17 56.7
Chronic persistent hepatitis (CPH) 1 3.3
Cholestasis 3 10.0
Liver carcinoma 1 3.3
Minimal changes 6 20.0
Tuberculosis 1 3.3
Normal liver 1 3.3
Total 30 100.0
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Other factors that were associated with HIV and viral
hepatitis were: use of non-disposable needles
(55.6%), previous surgery (55.6%); tattoos (31.5%),
blood transfusion (14.6%) and acupuncture (2.2%).
Daily alcohol consumption was reported by 14%.
Abuse of non-alcohol drugs was cited by 13% of the
patients, 13 of 30 of whom were intravenous users,
while 23 of 30 used inhalation as the administration
route. Hepatotoxic drug use was reported by 33.2%.
However, there was no significant association between
these factors and qALT>1 (p>0.05). Prior hepatitis
was reported by 15% of the patients, but the
etiological agents were unknown.
We found that 28.4% of the patients had some
symptoms of digestive tract disorder, nausea
(23.7%) being the most frequently reported
symptom, while 10.3% complained of diarrhea and
9.5% complained of vomiting. Jaundice was cited
by 4.3% of the patients, but only two complained of
hematemesis. Only 3.5% presented moderate to
intense grade hepatomegaly (liver > 3 cm), while in
54.3% the liver was 0-3 cm from the right costal
margin and in 42.2% the liver was not palpable. The
presence of a palpable liver was significantly
correlated with qALT >1 (p = 0.0001). The spleen
was palpable in 12.5%, jaundice was found in 1.3%,
37.5% had cervical adenomegaly and one patient
had the clinical features of portal hypertension.
Table 1 shows the results of the biochemical tests.
Of the 49 patients with elevated AST levels, 22 used
some kind of hepatotoxic medication, while among
the 182 patients with normal AST, 55 (30%) also
used hepatotoxic medication; patients who used
hepatotoxic medication were significantly more likely
to have high AST levels. Of the 17 patients with
elevated AP levels, three had tuberculosis. Ten
subjects with elevated AP levels were submitted to
abdominal ultrasound but neither adenomegaly nor
cholestasis were found. Among the 10 patients with
hypoalbuminemia, five were classified in group IV
of the CDC classification.
Table 2 shows the results of the serological tests
for HAV, HBV and HCV. Of the 156 patients tested,
93.6% were anti-HAV IgG positive while one patient
was anti-HAV IgM positive. Among the 226
patients, 5.3% were HBsAg positive and 44.2%
anti-HBcAg positive. Seventy-nine of 224 (35.3%)
patients were anti-HBsAg positive and 119 of 221
(53.8%) of the patients were anti-HCV positive.
Table 3 shows the distribution of only anti-HBcAg
or only anti-HCV positive patients, with respect to
HIV transmission route. There was a significant
association(p=0.001) between these factors, and we
observed that patients whose probable HIV
transmission route was by blood had a 10.8 times
greater risk of being anti-HCV positive than those
whose probable HIV transmission route was sexual
intercourse.
Table 4 shows the probable risk factors involved in
hepatic lesions based on qALT values. Among 92
patients with qALT >1, 4% had no detectable hepatic
lesions, although one presented cervical
adenomegaly that later was diagnosed as ganglionic
tuberculosis and one had syphilis (VDRL=1/128).
Table 4 also shows that 45.6% of the 92 patients
with qALT >1 had only one casual risk factor for
hepatic lesion, i.e. HBV or HCV infection, use of
hepatotoxic or illicit drugs or alcohol abuse. One of
the 92 patients had all the risk factors that we
investigated. If we consider all the individuals with
qALT >1 and that presented a viral hepatitis marker,
we see that 66.3% were positive for anti-HCV and
four (4%) were co-infected with HBV and HCV.
The factor that gave a significant association with
patients who had a qALT>1 was a positive anti-
HCV test (p=0.0001) .
Thirty patients agreed to have a liver biopsy (table
5); 18 presented chronic hepatitis and one had a
normal liver.
Discussion
In 50% of our patients, sexual intercourse was the
principal risk factor for HIV infection. This route of
transmission is associated with about half of the cases
of AIDS in adults in Brazil [10-11]. HIV transmission
by blood probably occurred in 32% of our patients,
with 29% being associated with IVDU. Official figures
Viral Hepatitis and HIV
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for the state of São Paulo [11] show that 35% of the
AIDS cases in this region are related to IVDU, which
indicates that the population studied by us was
representative of the HIV-infected adult population in
our part of Brazil.
Neither alcoholism nor IVDU was significantly
associated with high ALT levels in our group of
patients, although elevated ALT levels did
significantly correlate with HCV infection, and
hepatomegaly and high AST levels were associated
with hepatotoxicity. We consider that all HIV-
positive patients with elevated ALT levels are at risk
of HCV infection and should be investigated. A large
number of AIDS patients are at present undergoing
potentially hepatotoxic highly active antiretroviral
therapy (HAART) therapy, and these patients must
have their AST levels periodically measured.
About 28% of the patients in our study complained
of gastrointestinal symptoms, nausea and vomiting being
the most common (about 33%) with previous jaundice
(4.3%) and hematemesis (1%) being uncommon, while
at clinical evaluation only 1.3% were diagnosed as
having jaundice and about 0.5 % had portal
hypertension. In our clinical experience, about 94% of
the anti-HCV positive blood donors who are anti-HIV
negative have no symptoms of jaundice, and only 2%
report previous jaundice [12]. In the group of HIV-
positive patients investigated in our current 1study, there
were usually no symptoms of viral hepatitis (a few
patients showed mild symptoms), just as was the case
in HIV-negative patients with chronic viral hepatitis C
seen in our general practice.
In general, HIV and HCV positive patients have a
higher frequency of hepatomegaly when compared with
patients infected only with HCV [2]. This may be
explained by the presence of another hepatotropic virus,
opportunistic infections, or the use of medication.
Elevated ALT levels are frequently observed in HIV-
infected subjects and may also be associated with
hepatotoxic drugs, bad nutrition, cardiac insufficiency,
hypoxia, medical procedures and blood transfusions.
The majority of these factors were absent from our
group of patients with elevated ALT levels.
In 17 (8%) of our patients, AP levels were
levated, probably due to intrahepatic cholestasis
or hilar adenomegaly (each of which may be present
in cases of tuberculosis), tuberculosis being detected
in three of 17 of these patients. In our opinion all
HIV-infected patients with elevated AP levels should
be submitted to liver biopsy, especially if they have
fever.
Hypoalbuminemia was present in 5% of our
patients, this being common in AIDS patients, due
to bad nutrition, and 50% of our patients had
opportunistic infections. It appears that both AIDS
and opportunistic infections were important factors
in patients’ hypoalbuminemia, which was itself made
worse by concomitant HBV or HCV infections.
Elevated gamma-globulin levels were very frequently
observed in our group of AIDS patients, but it was
not associated with advanced liver disease.
About 94% of our patients had anti-HAV IgG in
their serum. There is a higher risk of HAV infection
among homosexual men [3] and IVDU [13], both
of these being high risk groups for HIV infection. A
high prevalence of anti-HAV has also been observed
among HIV-negative adults in developing and newly
industrialized countries, such as Brazil [14].
There were 12 (5.3%) HbsAg-positive patients
in our group, this being about three times higher than
the frequency found in a group of blood donors
previously studied by us [15]. Six (50%) of our
HbsAg-positive patients were IVDU, two (16.7%)
were homosexual males, one (8%) was a bisexual
male, one (8%) was a promiscuous heterosexual and
two (17%) presented more than one risk factor.
Different values have been found in other studies,
e.g. in Spain 5% of homosexual men were HBsAg
positive, 13% were IVDU and 2% of the patients’
exual partners were also HBsAg positive [16]; these
values were similar in both HIV-positive and
negative patients.
About 44% of our HIV-positive patients were
also anti-HBcAg positive. In the group of blood
donors that we had studied earlier [15], 11% were
anti-HBcAg positive. In the current study there was
no significant difference in the prevalence of anti-
HBcAg in IVDU (40%) and homosexuals (44%),
Viral Hepatitis and HIV
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but when the relationship between the presence of
anti-HBcAg and mode of transmission was analyzed
it was found that HIV-positive patients who had been
contaminated by the sexual route had a significantly
higher prevalence of anti-HBcAg than patients
contaminated by blood. These results reflect the
importance of the sexual transmission of HBV. In
some patients anti-HBcAg may act as the only HBV
infection for several reasons, e.g. undetectable levels
of HBsAg in a serological test (the so-called
immunological window), deficient production of anti-
HBsAg caused by genetic factors, loss of HBsAg in
very old infections, passive transmittance of anti-
HBcAg by drug users, a false positive EIA test result,
or interference caused by the presence of other
viruses. In our study, 25 patients, 48% of whom
were IVDU, presented anti-HBcAg as the only HBV
marker. It appears that some patients co-infected
with HIV are unable to produce anti-HBsAg during
HBV infection. This atypical feature of HBV infection
has been observed in 10.7% of IVDU in England
and 35% in Italy [17].
The anti-HBsAg antibody was present in 35.3%
of our patients, lower than the 65% found in patients
with advanced HIV infection [18]. Another study
[16] found anti-HBsAg in 88% of IVDU, 70% of
homosexual men and 26% among sexual partners
of IVDU. In our study, 15 patients presented only
anti-HBsAg as a marker of previous HBV infection.
These patients had not previously been immunized
against HBV and it seems that they had lost the other
anti-HBV markers due to HIV infection. No
significant correlation was observed between the
presence of HBV markers and elevated ALT levels.
About 54% of our patients were anti-HCV positive,
which is very much higher than the 2.6% anti-HCV
positive found in blood donors from the region of
Campinas [15]. When the probable route of HIV
transmission was by blood we noted a higher rate
of positive anti-HCV tests (84.4%) when compared
to that observed in patients whose probable HIV
transmission route was sexual intercourse (33.3%).
This correlation was significant and confirms that
hepatitis C is very common when HIV infection is
acquired by exposure to infected blood. The
prevalence of positive anti-HCV tests was high
among IVDU (90%) and low among homosexual
men (3.7%), while among promiscuous heterosexuals
there was a higher prevalence of HCV (43.5%) than
in homosexuals (3.7%). A study involving the sexual
partners of patients with hemophilia [7] found that
the rate of HCV transmission was five times higher
in the presence of concomitant HIV transmission; it
may be that HIV is an important cofactor for the
sexual transmission of HCV.
Some authors [19,20,21] consider that anti-HCV
tests can present false positives in patients with HIV
infection due to the high levels of circulating antibodies,
while others argue that anti-HCV tests can give false
negative results in cases of advanced AIDS because
of decreased antibody production [22]. Some studies
have shown a good correlation between the results of
anti-HCV tests by EIA-2 and tests involving HCV
RNA using the polymerase chain reaction (PCR); one
such study showed that in groups with high risk for
HCV infection about 93% of the positive anti-HCV
EIA-2 tests were positive for the immunoblot test for
HCV (RIBA-2), and 85% of them were HCV RNA
positive [23-24]. In our opinion, anti-HCV positive
patients should always be considered as HCV infected,
which may be confirmed by detecting HCV-RNA using
PCR.
With regard to our findings concerning ALT, other
authors have also observed an association between
positive anti-HCV test and elevated plasma ALT [20-
24]. We consider that the cytopathic effect of HCV in
the liver may be amplified when the patient is co-infected
with HIV.
We encountered chronic hepatitis in 60% of the
liver biopsies from HIV patients (only 3.3% had a
normal liver) and 70% of our anti-HCV positive
patients had CAH, which demonstrates the
importance of liver biopsy in co-infected patients.
In the past a great number of opportunistic infections
have been seen in liver biopsies of HIV-infected
patients because such patients normally had
advanced AIDS [25-26-27]. In more recent studies,
patients without advanced AIDS have been
Viral Hepatitis and HIV
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evaluated, and we have observed histopathological
lesions similar to those found in patients with HCV
but without HIV. In such cases, changes such as
CAH and CH, which are associated with
hepatotropic virus, predominate [28].
In HIV patients co-infected with HBV the liver
biopsies showed mild lesions, when compared to
the histopathological alterations present in anti-HIV
negative patients [29]; it seems that HBV is not
cytopathic for hepatocytes. The mild liver lesions
observed in our HBV infected patients reflects a
deficient cellular immune response to infected
hepatocytes in patients with HIV infection. The
occurrence of the more severe lesions, which were
observed in HCV patients co-infected with HIV
suggests, and perhaps confirms, the predominantly
cytopathic action of HCV in the liver [9].
In conclusion, the occurrence of viral hepatitis in
our group of Brazilian HIV-infected patients is common
and it affects the clinical course of both infections. The
advent of highly effective anti-HIV therapy has given
AIDS patients both prolonged survival and a better
quality of life, but an increased incidence of end-stage
liver disease is now being observed among these
patients and this will oblige us to find better ways to
treat the chronic liver diseases caused by hepatotropic
viruses.
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